Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

October 5, 2020

Read the press release in Swedish: 

Download press release (pdf)
< Back to press releases
Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Org.nr: 556966-4955.
Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬